Louis J. Lavigne, Jr.
After 23 years with Genentech, Inc., Lavigne is now a management consultant specializing in the areas of corporate finance, accounting and strategy. He retired as Executive Vice President and Chief Financial Officer of Genentech in March, 2005. He joined Genentech in July,1982 and was named Controller in 1983 and built Genentech’s operating financial functions. In 1986, he was promoted to Vice President and assumed the CFO position in September 1988. He became Senior Vice President in July,1994 and Executive Vice President in March,1997. Lavigne was a member of Genentech’s Executive Committee and chairman of its 401K Plan Committee. Genentech's revenues grew significantly during Lavigne’s tenure: from $40 million when he became Controller in 1983, to ~ $300 million when he became CFO in 1988 and were over $6.6 billion in 2005.
Lavigne was responsible for Genentech’s Financial, Corporate Relations, and Information Technology groups and was named the Best CFO in Biotech in 2005 in the Institutional Investor survey. In June, 2006, he received the Bay Area CFO of the Year-Hall of Fame-Lifetime Achievement Award.
Prior to joining Genentech, Lavigne held various financial management roles with Pennwalt Corporation, a chemical and pharmaceutical company.
He is a member of the Board of Directors of Accuray Incorporated (and Chairman of the Board & Compensation Committee), Zynga, Inc., Depomed, Inc., DocuSign Inc., Novocure Limited, Puppet, Inc. and Rodan & Fields. Previously he was a Director and Chairman of the Audit Committee of several other public companies: Allergan, Inc., Arena Pharmaceuticals, BCM Software, Equinix, Kyphon, SafeNet, Inc. and Xenova, PLC. He is also member of the Pacific SW Audit Committee Network of Audit Committee Chairs.
He is a member of the Board and former Chairman of UCSF Benioff Children's Hospitals and their foundation.
Lavigne earned a bachelor’s degree in business administration from Babson College in 1969 and an M.B.A. from Temple University in 1976.
Class II Director, Term Expires 2020